In locally advanced esophageal cancer patients PD-L1 expression is correlated with poorer overall survival and its expression in tumor cells increased in esophageal cancer patients after neoadjuvant CRT hence supporting the rationale of PD-L1 blockade in combination with CRT [7]. The gene discussed is CD274; the disease is neoplasm.